avalglucosidase alfa
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II
Conditions
Glycogen Storage Disease Type II
Trial Timeline
Sep 1, 2021 → Aug 10, 2027
NCT ID
NCT04910776About avalglucosidase alfa
avalglucosidase alfa is a phase 3 stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is active. This product is registered under clinical trial identifier NCT04910776. Target conditions include Glycogen Storage Disease Type II.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06666413 | Approved | Recruiting |
| NCT04910776 | Phase 3 | Active |
| NCT02032524 | Phase 2 | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type II